Morgan Stanley Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $146
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT), but lowered the price target from $183 to $146.
October 31, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Sarepta Therapeutics, but lowered the price target from $183 to $146.
The news is directly related to Sarepta Therapeutics. While the Overweight rating indicates that Morgan Stanley expects the stock to outperform the market, the lowering of the price target may create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100